CytomX Therapeutics (CTMX) Stock Price, News & Analysis

Company Overview

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for cancer and other serious diseases. The company’s technology is designed to keep therapeutic antibodies inactive in healthy tissue and activate them in disease sites, particularly within the tumor microenvironment, with the goal of improving treatment precision and reducing systemic toxicity.

CytomX’s Probody Therapeutics platform uses conditionally activated antibodies and related molecules. Its pipeline has included masked monoclonal antibodies, bispecific T-cell engagers and other immune-modulating therapies directed at targets such as EGFR and CTLA-4. The company advances programs independently and through collaborations with larger pharmaceutical and biotechnology companies.

Founded in 2008 and headquartered in South San Francisco, California, CytomX has developed a global business through research, clinical development and strategic partnerships. Its partnered programs and clinical trials extend the potential reach of its platform beyond the United States, while the company remains primarily focused on advancing oncology medicines toward clinical proof of concept and potential commercialization.

Key Stats

• Today's Range: $2.43 to $2.55
• 50-Day Range: $2.47 to $3.72
• 52-Week Range: $2.43 to $8.21
• Volume: 4.50 million shs
• Average Volume: 4.09 million shs
• Market Capitalization: $538.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.90
• Consensus Rating: Moderate Buy

CytomX Therapeutics Stock Analysis - MarketRank™

CytomX Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 704th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CytomX Therapeutics has a consensus price target of $11.90, representing about 381.8% upside from its current price of $2.47.

Amount of Analyst Coverage

CytomX Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CytomX Therapeutics is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytomX Therapeutics is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CytomX Therapeutics has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.43% of the float of CytomX Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytomX Therapeutics has a short interest ratio ("days to cover") of 9.29.

Change versus previous month

Short interest in CytomX Therapeutics has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytomX Therapeutics does not currently pay a dividend.

Dividend Growth

CytomX Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.46

News Sentiment

CytomX Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CytomX Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.80% of the stock of CytomX Therapeutics is held by insiders.

Percentage Held by Institutions

67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CTMX
• CIK: 1501989
• Web: www.cytomx.com
• Phone: (650) 515-3185
• Fax: 650-351-0353
• Employees: 69
• Year Founded: 2008

Price Target and Rating

• Average Price Target for CytomX Therapeutics: $11.90
• High Price Target: $16.00
• Low Price Target: $6.00
• Potential Upside/Downside: +381.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.37 million
• Net Margins: -435.21%
• Pretax Margin: -433.95%
• Return on Equity: -38.46%
• Return on Assets: -30.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.36
• Quick Ratio: 9.36

Sales & Book Value

• Annual Sales: $18.30 million
• Price / Sales: 29.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 4.26

Miscellaneous

• Outstanding Shares: 217,899,000
• Free Float: 209,619,000
• Market Cap: $538.21 million
• Optionable: Optionable
• Beta: 2.21